1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022


Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Saphris (asenapine maleate), also known as Sycrest in the EU, is a dibenzazepine neuroleptic. The drug utilizes the tricyclic dibenzazepine heterocycle as a basic structural feature which is lipophilic in its nature, allowing Saphris to cross the blood-brain barrier with less resistance. Unlike Abilify, Saphris acts as an antagonist at dopamine D2 receptors, meaning that Saphris can effectively target positive psychotic symptoms associated with schizophrenia; however, it has a higher chance of causing extrapyramidal symptoms over the long term.


- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Saphris including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Saphris for the top six countries from 2012 to 2022.
- Sales information covered for the US, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Saphris performance
- Obtain sales forecast for Saphris from 2012-2022 in the top six countries (the US, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 15
4.1 Diagnosis 15
4.1.1 Subjective Assessments 16
4.1.2 Disease Subtypes 17
4.2 Treatment Overview 20
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 22
4.2.2 Maintenance Treatment of Schizophrenia 23
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Saphris (asenapine maleate) 28
6.1 Overview 28
6.2 Efficacy as an Acute Treatment 29
6.3 Efficacy as a Maintenance Treatment 30
6.4 Safety 30
6.5 SWOT Analysis 31
6.6 Forecast 31
7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 35
7.3 Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Diagnosis and Treatment Rates 36
7.4.2 Adherence Rates 37
7.4.3 General Pricing Assumptions 37
7.4.4 Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Key Opinion Leaders 40
7.6 About the Authors 41
7.6.1 Author 41
7.6.2 Reviewers 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 14
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 17
Table 3: Development-Based Classification of Antipsychotic Drugs 20
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 21
Table 5: Guidelines for the Treatment of Schizophrenia 22
Table 6: Leading Branded Treatments for Schizophrenia, 2013 27
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 27
Table 8: Product Profile - Saphris 29
Table 9: Saphris SWOT Analysis, 2013 31
Table 10: Global Sales Forecast ($m) for Saphris, 2012-2022 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.